Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 914009-84-0 elsiglutide in China, also supports custom service. Welcome to wholesale bulk high quality cas 914009-84-0 elsiglutide from our factory. Contact us for more details.
| Product name | CAS:914009-84-0:Elsiglutide |
| Description | Elsiglutide is a structurally optimized long‑acting GLP‑2 receptor high‑selectivity agonist. N‑terminal site mutation significantly enhances resistance to dipeptidyl peptidase IV (DPP‑IV) degradation and greatly extends in vivo duration. It specifically binds to GLP‑2 receptors on intestinal epithelial cells, promotes intestinal epithelial cell proliferation, inhibits apoptosis, increases intestinal mucosal thickness and nutrient absorption area, while enhancing intestinal barrier integrity and reducing inflammation‑mediated mucosal damage. Widely applied in mechanism research and gastrointestinal repair peptide drug development for short bowel syndrome, chemotherapy‑induced mucositis, inflammatory bowel disease and intestinal injury repair. |
| Peptide purity (HPLC, %) | 95%/98%/99% |
| Theoretical molecular formula | C₁₆₆H₂₅₆N₄₄O₅₅S |
| Theoretical molecular weight (Da) | ~3769.20 (subject to actual synthetic batch) |
| Structure type | Site‑mutated modified GLP‑2 analog, 33‑mer linear polypeptide |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Modification Type | Length (aa) |
| Elsiglutide | Elsiglutide; ZP1848; GLP-2 analog | Intestinal mucosal repair,GLP-2 receptor agonism,Short bowel syndrome study,DPP-IV degradation resistant,Intestinal barrier protection,Gastrointestinal peptide | 33-mer linear backbone with Ala→Gly site mutation at position 2 | C₁₆₆H₂₅₆N₄₄O₅₅S (theoretical) | 3767.85 | 3769.2 | Single amino acid site mutation | 33 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage Conditions | Short-term Storage Conditions | Liquid Stability | Solid Powder Stability |
| PEP-ELG001 | white powder | Store at -20℃, sealed, dry & protected from light, aliquoted; avoid repeated freeze-thaw cycles | Solid powder stable for 1 month at 2-8℃ sealed & dry; prepare aqueous solutions freshly before use | Stable for 72 h at 4℃; stable for 1 month at -20℃ in aliquots. **Good water solubility, freely soluble in water and neutral physiological buffer**. DPP-IV resistance significantly improved, but still prone to endopeptidase degradation. Methionine prone to oxidation | Stable for 2 years at -20℃ under dry & dark conditions |
Functional Description
| Product Code | Frontend Short Summary (for search list display) | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-ELG001 | Long-acting GLP-2 receptor agonist that promotes intestinal epithelial proliferation/repair, enhances intestinal barrier and improves absorptive function in short bowel syndrome | By mimicking the physiological function of endogenous GLP-2, Elsiglutide activates GLP-2 receptors on the surface of intestinal epithelial cells and crypt cells with high selectivity, initiates downstream cAMP/PKA and PI3K/Akt signaling pathways, promotes crypt stem cell proliferation and differentiation, accelerates intestinal epithelial cell renewal, increases villus height and mucosal thickness, and expands intestinal nutrient absorption area. Meanwhile, it inhibits epithelial cell apoptosis, upregulates tight junction protein expression, enhances intestinal mechanical barrier function, reduces endotoxin and inflammatory factor translocation, and alleviates intestinal inflammatory damage. Compared with native GLP-2, its amino acid mutation at position 2 avoids rapid enzymatic cleavage by DPP-IV, extending in vivo half-life by several folds with longer lasting effect. This molecule serves as a core tool peptide for intestinal compensation in short bowel syndrome, chemotherapy-induced intestinal mucosal injury repair, mucosal protection in inflammatory bowel disease and intestinal barrier function research, as well as a lead molecule for the development of new-generation gastrointestinal repair peptide drugs. | Short bowel syndrome research,Chemotherapy-induced intestinal mucositis,Inflammatory bowel disease study,Intestinal barrier function,Gastrointestinal repair peptide,Intestinal mucosal regeneration | Glucagon-Like Peptide-2 Receptor (GLP-2R); cAMP/PKA and PI3K/Akt signaling pathways; Intestinal epithelial proliferation and mucosal repair pathway |
Hot Tags: cas 914009-84-0 elsiglutide, China cas 914009-84-0 elsiglutide manufacturers, suppliers, factory, CAS 129954 34 3, CAS 1415456 99 3, CAS 2381089 83 2, Melanotan II, pharmaceutical peptides, Semaglutide
